Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and Tamoxifen in Refractory Ovarian Cancer
NCT00189358Phase 2Completed
- Sponsor
- AGO Study Group
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Study Group. Status: completed.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00189358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189358.